Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.12 
Mean NPI-X Total Score from Week 4 through Week 24 - Windowed 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline 
value as a covariate. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=79)  
Xanomeline 
 Low Dose 
 (N=81)  
Xanomeline 
 High Dose 
 (N=74)  
Baseline 
  n                                   79 
  81 
  74 
  Mean (SD)                            9.5 (12.10) 
   8.7 (9.82) 
  11.9 (13.70) 
  Median (Range)                       5.0 (0;66) 
   4.0 (0;32) 
   8.0 (0;61) 
Mean of Weeks 4-24 
  n                                   78 
  75 
  69 
  Mean (SD)                            9.3 (11.18) 
   9.1 (12.10) 
   9.6 (11.60) 
  Median (Range)                       5.5 (0;65) 
   3.8 (0;51) 
   4.4 (0;46) 
 
  p-value(Dose Response) [1][2]     
 
 
  0.637 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.760 
   0.517 
   Diff of LS Means (SE)            
 
0.3 (1.13) 
-0.7 (1.15) 
   95% CI                           
 
(-1.9;2.6) 
(-3.0;1.5) 
 
  p-value(Xan High - Xan Low) [1][3]
 
 
   0.350 
   Diff of LS Means (SE)            
 
 
-1.1 (1.17) 
   95% CI                           
 
 
(-3.4;1.2) 
 
